Alefacept

Title: Alefacept
CAS Registry Number: 222535-22-0
CAS Name: 1-92-LFA-3 (antigen) (human) fusion protein with immunoglobulin G1 (human hinge-CH2-CH3 g1-chain), dimer
Additional Names: human LFA-3-IgG1 fusion protein; LFA3TIP
Manufacturers' Codes: BG-9273; BG-9712
Trademarks: Amevive (Biogen)
Literature References: Recombinant fusion protein consisting of the first extracellular domain of human leukocyte function-associated antigen-3 (LFA-3) fused to the hinge and CH2 and CH3 sequences of human IgG1. Expressed in Chinese hamster ovary cells; secreted as a glycosylated dimer, mol wt ~110 kDa. Antagonist at the CD2 receptor on T-lymphocytes and NK cells; inhibits T-cell proliferation. Prepn: B. P. Wallner et al., EP 503648; eidem, US 5547853 (1992, 1996 both to Biogen); and binding study: G. T. Miller et al., J. Exp. Med. 178, 211 (1993). Pharmacology and ELISA determn in serum: P. L. Chisholm et al., Ther. Immunol. 1, 205 (1994). Effect of glycosylation on pharmacokinetics: W. Meier et al., ibid. 2, 159 (1995). Mechanism of action study: F. Chamian et al., Proc. Natl. Acad. Sci. USA 102, 2075 (2005). Clinical trial in psoriasis: C. N. Ellis et al., N. Engl. J. Med. 345, 248 (2001). Safety profile: B. Goffe et al., Clin. Ther. 27, 1912 (2005). Review of clinical development in psoriasis: R. G. Langley et al., Expert Opin. Pharmacother. 6, 2327-2333 (2005).
Therap-Cat: Antipsoriatic; immunosuppressant.
Keywords: Antipsoriatic; Immunosuppressant.
Alemtuzumab Alendronic Acid Aleuritic Acid Alexidine Alexitol Sodium

Alefacept
Systematic (IUPAC) name
1-92-LFA-3 (Antigen) (human) fusion protein with immunoglobin G1 (human hinge CH2-CH3γ1-chain) dimer
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a603011
Pregnancy cat. C (AU) B (US)
Legal status -only (US)
Routes Intravenous, intramuscular
Pharmacokinetic data
Bioavailability 63% (IM)
Half-life ~270 hours
Identifiers
CAS number 222535-22-0 YesY
ATC code L04AA15
DrugBank DB00092
UNII ELK3V90G6C YesY
KEGG D02800 YesY
ChEMBL CHEMBL1201571 N
Chemical data
Formula C2306H3594N610O694S26 
Mol. mass 51801.1 g/mol
 N (what is this?)  (verify)

Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc. (http://www.amevive.com/Patient%20letter.pdf), the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.

Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation.[1] It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.

Alefacept is a fusion protein: it combines part of an antibody with a protein that blocks the growth of some types of T cells.